Article Sidebar

PDF
Date Published: 17/10/2022
Abstract Views: 401
Views PDF: 368
DOI: https://doi.org/10.51298/vmj.v519i1.3562
Issue
Vol. 519 No. 1 (2022)
Section
Các bài báo
How to Cite
Minh Lanh, P. ., Công Minh, T. ., & Cẩm Phương, P. . (2022). THE EFFICACY OF PEMBROLIZUMAB PLUS CHEMOTHERAPPY IN PATIENTS WITH STAGE IV NON SMALL CELL LUNG CANCER. Vietnam Medical Journal, 519(1). https://doi.org/10.51298/vmj.v519i1.3562

THE EFFICACY OF PEMBROLIZUMAB PLUS CHEMOTHERAPPY IN PATIENTS WITH STAGE IV NON SMALL CELL LUNG CANCER

Phạm Minh Lanh1,, Trương Công Minh2, Phạm Cẩm Phương3
1 Hanoi Medical University
2 Vietnam National Cancer Hospital
3 Nuclear Medicine and Oncology Center, Bach Mai Hospital

Main Article Content

Abstract

Objectives: To evaluate the efficacy of pembrolizumab plus platinum-doublet chemotherapy in patients with stage IV non-small cell lung cancer. Patients and methods: Retrospective, descriptive study on 41 patients with stage IV non-small cell lung cancer who had received first line treatment with pembrolizumab plus platinum-based chemotherapy from 1/2020 to 07/2022 at Bach Mai Hospital and Vietnam National Cancer Hospital.  Results:  The overall response rate was 61%, the disease control rate was  83%. The median progression-free survival was 11,9 months. The most common advese aevents were anemia (70,7%), neutropenia (41,5%), thrombocytopenia (14,6%), aminotransferase increased (31,7%), pneumonitis (4,9%), creatinin evalated (9,8%). Conclusion: The pembrolizumab plus platinum-doublet chemotherapy improves the result of treamment while toxicities were acceptable for major patients.

Article Details

Keywords

Non small cell lung cancer, immunotherapy, pembrolizumab plus chemotherapy

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15-25. doi:10.1038/cdd.2013.67
3. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. N Engl J Med. 2015;372(21):2018-2028. doi:10.1056/NEJMoa1501824
4. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer | NEJM. Accessed August 13, 2022. https://www. nejm.org/doi/full/10.1056/NEJMoa1810865
5. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer | NEJM. Accessed August 13, 2022. https:// www.nejm.org/doi/full/10.1056/nejmoa1801005
6. Socinski MA, Obasaju C, Gandara D, et al. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018; 13(2):165-183. doi:10.1016/j.jtho.2017.11.111